Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phas… Read more
Medivir AB (publ) (MVR0) - Net Assets
Latest net assets as of September 2025: €65.40 Million EUR
Based on the latest financial reports, Medivir AB (publ) (MVR0) has net assets worth €65.40 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€130.90 Million) and total liabilities (€65.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €65.40 Million |
| % of Total Assets | 49.96% |
| Annual Growth Rate | -25.65% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.44 |
Medivir AB (publ) - Net Assets Trend (2021–2024)
This chart illustrates how Medivir AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medivir AB (publ) (2021–2024)
The table below shows the annual net assets of Medivir AB (publ) from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €115.52 Million | -46.99% |
| 2023-12-31 | €217.93 Million | +13.04% |
| 2022-12-31 | €192.79 Million | -31.43% |
| 2021-12-31 | €281.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medivir AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 31608000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €980.01 Million | 848.38% |
| Total Equity | €115.52 Million | 100.00% |
Medivir AB (publ) Competitors by Market Cap
The table below lists competitors of Medivir AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mineral Commodities Ltd
AU:MRC
|
$15.81 Million |
|
OPCOM Holdings Bhd
KLSE:0035
|
$15.81 Million |
|
Ado Optronics
TWO:3516
|
$15.82 Million |
|
Sonic Interfreight Public Company Limited
BK:SONIC
|
$15.83 Million |
|
TPC Power Holding Public Company Limited
BK:TPCH
|
$15.81 Million |
|
FOMTF
PINK:FOMTF
|
$15.80 Million |
|
Acon Optics Communications Inc.
TWO:6820
|
$15.79 Million |
|
INTERSHOP Communications Aktiengesellschaft
XETRA:ISHA
|
$15.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medivir AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 217,924,000 to 115,516,000, a change of -102,408,000 (-47.0%).
- Net loss of 123,317,000 reduced equity.
- New share issuances of 20,370,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-123.32 Million | -106.75% |
| Share Issuances | €20.37 Million | +17.63% |
| Other Changes | €539.00K | +0.47% |
| Total Change | €- | -46.99% |
Book Value vs Market Value Analysis
This analysis compares Medivir AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.05x to 0.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €4.13 | €0.22 | x |
| 2022-12-31 | €2.83 | €0.22 | x |
| 2023-12-31 | €2.09 | €0.22 | x |
| 2024-12-31 | €1.03 | €0.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medivir AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -106.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3539.52%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.49x
- Recent ROE (-106.75%) is below the historical average (-54.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -22.45% | -247.19% | 0.08x | 1.19x | €-91.24 Million |
| 2022 | -46.04% | -2013.73% | 0.02x | 1.21x | €-108.04 Million |
| 2023 | -40.99% | -1170.06% | 0.03x | 1.32x | €-111.11 Million |
| 2024 | -106.75% | -3539.52% | 0.02x | 1.49x | €-134.87 Million |
Industry Comparison
This section compares Medivir AB (publ)'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medivir AB (publ) (MVR0) | €65.40 Million | -22.45% | 1.00x | $15.81 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |